Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy | Zendy

Efstathios Kastritis | Zendy; MariaChristina Kyrtsonis | Zendy; Pierre Morel | Zendy; Maria Gavriatopoulou | Zendy; E. Hatjiharissi | Zendy; Argiris Symeonidis | Zendy; Amalia Vassou | Zendy; Panagiotis Repousis | Zendy; Sosana Delimpasi | Zendy; Anastasia Sioni | Zendy; E. Michalis | Zendy; Michalis Michael | Zendy; E. Vervessou | Zendy; Michael Voulgarelis | Zendy; C. Tsatalas | Zendy; Evangelos Terpos | Zendy; Meletios Α. Dimopoulos | Zendy

Open Access

Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

Author(s) -

Efstathios Kastritis,

MariaChristina Kyrtsonis,

Pierre Morel,

Maria Gavriatopoulou,

E. Hatjiharissi,

Argiris Symeonidis,

Amalia Vassou,

Panagiotis Repousis,

Sosana Delimpasi,

Anastasia Sioni,

E. Michalis,

Michalis Michael,

E. Vervessou,

Michael Voulgarelis,

C. Tsatalas,

Evangelos Terpos,

Meletios Α. Dimopoulos

Publication year - 2015

Publication title -

haematologica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.782

H-Index - 142

eISSN - 1592-8721

pISSN - 0390-6078

DOI - 10.3324/haematol.2015.124149

Subject(s) - medicine , rituximab , waldenstrom macroglobulinemia , disease , macroglobulinemia , oncology , survival analysis , pediatrics , lymphoma , multiple myeloma

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog